Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

PHASE2CompletedINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions

Mammographically Dense Breast

Interventions

DRUG

Afimoxifene

Applied topically

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Applied topically

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (5)

Columbia University/Herbert Irving Cancer Center, New York

Moffitt Cancer Center, Tampa

Northwestern University, Chicago

M D Anderson Cancer Center, Houston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03063619 - Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast | Biotech Hunter | Biotech Hunter